Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes
- Conditions
- Breast Cancer
- Interventions
- Registration Number
- NCT00003782
- Lead Sponsor
- NSABP Foundation Inc
- Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any tumor cells remaining following surgery. It is not yet known which regimen of combination chemotherapy is more effective in treating breast cancer with positive axillary lymph nodes.
PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of combination chemotherapy in treating women who have undergone surgery for stage I, stage II, or stage IIIA breast cancer with positive axillary lymph nodes.
- Detailed Description
OBJECTIVES:
* Compare the efficacy of adjuvant doxorubicin, cyclophosphamide, and docetaxel given concurrently vs adjuvant doxorubicin and cyclophosphamide followed by docetaxel, in terms of overall survival and disease-free survival, of women with breast cancer and positive axillary lymph nodes.
* Compare the efficacy of adjuvant doxorubicin and docetaxel vs regimens containing cyclophosphamide in these patients.
* Compare the toxic effects of these regimens in these patients.
* Compare the quality of life of patients treated with these regimens. (Quality of life substudy closed to accrual as of 7/20/01.)
* Compare the differences in amenorrhea in premenopausal women in each treatment arm and its relationship to symptoms, quality of life (quality of life substudy closed to accrual as of 7/20/01), disease-free survival, and overall survival.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, number of positive nodes (1-3 vs 4-9 vs at least 10), sequential tamoxifen or anastrozole administration (yes vs no), and type of prior surgery and radiotherapy plan (mastectomy with no local or regional radiotherapy vs mastectomy with local and/or regional radiotherapy vs lumpectomy with local radiotherapy vs lumpectomy with local and regional radiotherapy). Patients are randomized to one of three treatment arms.
* Arm 1: Patients receive doxorubicin IV over 15 minutes and cyclophosphamide IV over 30 minutes every 21 days for 4 courses. Three weeks after the last dose of this combination, patients receive docetaxel IV over 1 hour every 21 days for 4 courses.
* Arm 2: Patients receive doxorubicin IV over 15 minutes and docetaxel IV over 1 hour every 21 days for 4 courses.
* Arm 3: Patients receive doxorubicin IV over 15 minutes, cyclophosphamide IV over 30 minutes, and docetaxel IV over 1 hour every 21 days for 4 courses.
Patients in all arms who are estrogen receptor-positive and/or progesterone receptor-positive receive oral tamoxifen daily for 5 years beginning within 3-12 weeks of completion of chemotherapy. Patients who are postmenopausal may receive alternative hormonal therapy at the discretion of the treating physician.
Some patients may receive postmastectomy radiotherapy on SWOG-S9927 or NCIC-MA.20 after recovery from chemotherapy.
Quality of life and menstrual history are assessed before randomization, on day 1 of course 4, and at 6, 12, 18, and 24 months. (Quality of life substudy closed to accrual as of 7/20/01.)
Patients are followed every 6 months for 5 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 5,300 patients will be accrued for this study within 4-5 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 5351
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide cyclophosphamide Doxorubicin + Docetaxel + Cyclophosphamide Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel cyclophosphamide Doxorubicin + Cyclophosphamide, then Docetaxel Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel docetaxel Doxorubicin + Cyclophosphamide, then Docetaxel Arm 1: Doxorubicin + Cyclophosphamide, then Docetaxel doxorubicin Doxorubicin + Cyclophosphamide, then Docetaxel Arm 2: Doxorubicin + Docetaxel docetaxel Doxorubicin + Docetaxel Arm 2: Doxorubicin + Docetaxel doxorubicin Doxorubicin + Docetaxel Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide doxorubicin Doxorubicin + Docetaxel + Cyclophosphamide Arm 3: Doxorubicin + Docetaxel + Cyclophosphamide docetaxel Doxorubicin + Docetaxel + Cyclophosphamide
- Primary Outcome Measures
Name Time Method Overall Survival 8 years Disease Free Survival time to event: breast cancer recurrence; second primary cancer; death from any cause as a first event
- Secondary Outcome Measures
Name Time Method Quality of Life Among Breast Cancer Patients baseline, 9 weeks, and 6, 12, 18, and 24 months Toxicities Among the 3 Regimens 9 years Amenorrhea in Premenopausal Women baseline, 9 weeks, and 6, 12, 18, and 24 months
Trial Locations
- Locations (157)
Comprehensive Cancer Institute
🇺🇸Huntsville, Alabama, United States
Providence Alaska Medical Center
🇺🇸Anchorage, Alaska, United States
CCOP - Western Regional, Arizona
🇺🇸Phoenix, Arizona, United States
City of Hope Comprehensive Cancer Center
🇺🇸Duarte, California, United States
California Cancer Center
🇺🇸Fresno, California, United States
Sutter Health Western Division Cancer Research Group
🇺🇸Greenbrae, California, United States
Scripps Cancer Center at Scripps Clinic
🇺🇸La Jolla, California, United States
Rebecca and John Moores UCSD Cancer Center
🇺🇸La Jolla, California, United States
Loma Linda University Cancer Institute at Loma Linda University Medical Center
🇺🇸Loma Linda, California, United States
Pacific Shores Medical Group
🇺🇸Long Beach, California, United States
Scroll for more (147 remaining)Comprehensive Cancer Institute🇺🇸Huntsville, Alabama, United States